Výsledky vyhledávání

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to12 Years

Autor: A, Brochot, T N, Kakuda, T, Van De Casteele, M, Opsomer, F L, Tomaka, A, Vermeulen, P, Vis

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

An existing population pharmacokinetic model of darunavir in adults was updated using pediatric data from two studies evaluating weight-based, once-daily dosing of darunavir/ritonavir (ARIEL, NCT00919854 and DIONE, NCT00915655). The model was then us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::35cbcc080de8a8c0f3e25d7d64ef6556
https://pubmed.ncbi.nlm.nih.gov/26312164

Zobrazit plný text záznamu

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data

This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n = 999) vs. etravirine plus an alternative boosted protease inhibitor (other PI group; n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c52649908426c4eda6976b59a77b8a20
http://hdl.handle.net/2108/113124

Zobrazit plný text záznamu

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

Autor: G, Tudor-Williams, P, Cahn, K, Chokephaibulkit, J, Fourie, C, Karatzios, S, Dincq, M, Opsomer, T N, Kakuda, S, Nijs, L, Tambuyzer, F L, Tomaka, Leonard, Weiner

Publikováno v: HIV medicine. 15(9)

PIANO (Paediatric study of Intelence As an NNRTI Option; TMC125-C213; NCT00665847) assessed the safety/tolerability, antiviral activity and pharmacokinetics of etravirine plus an optimized background regimen (OBR) in treatment-experienced, HIV-1-infe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88fe7e7a6c70f1eedfc877a9baf304ef
https://pubmed.ncbi.nlm.nih.gov/24589294

Zobrazit plný text záznamu

Plný text ve formátu HTML

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial

Autor: M, Sension, P, Cahn, P, Domingo, S, Hodder, M, Opsomer, E, Lathouwers, T, Van de Casteele, F, Tomaka

Publikováno v: HIV medicine. 14(7)

ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized back

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e74e3c64cc1323f022ba9c1091401bbe
https://pubmed.ncbi.nlm.nih.gov/23480640

Zobrazit plný text záznamu

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

Autor: C, Orkin, E, DeJesus, H, Khanlou, A, Stoehr, K, Supparatpinyo, E, Lathouwers, E, Lefebvre, M, Opsomer, T, Van de Casteele, F, Tomaka

Publikováno v: HIV medicine. 14(1)

This paper presents the final analysis of once-daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment-naïve HIV-1-infected adults.ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naïve Subjects; NCT00258557) was a ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3803a50daf7261207779204c1b07f670
https://pubmed.ncbi.nlm.nih.gov/23088336

Zobrazit plný text záznamu

Efficacy and safety of rilmenidine in elderly patients—Comparison with hydrochlorothiazide

Autor: J. Verhaeghe, G. Creytens, W. Pelemans, G. Coupez, A. Van Dessel, M. Opsomer

Publikováno v: The American Journal of Cardiology. 74:A51-A57

The aim of this trial was to study the treatment of hypertension in the elderly, comparing a new oxazoline antihypertensive agent, rilmenidine, with the diuretic hydrochlorothiazide (HCZ). After 2 weeks on placebo, 88 elderly patients (mean age 75 ye

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84bf22e732c33672c001f8c0b2b0ab15
https://doi.org/10.1016/0002-9149(94)90042-6

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání